Hemostemix Inc. (CVE:HEM – Get Free Report) was up 46.7% on Friday . The stock traded as high as C$0.11 and last traded at C$0.11. Approximately 1,473,342 shares traded hands during mid-day trading, an increase of 283% from the average daily volume of 384,669 shares. The stock had previously closed at C$0.08.
Hemostemix Price Performance
The stock has a market capitalization of C$19.58 million, a price-to-earnings ratio of -2.97 and a beta of 1.39. The company has a debt-to-equity ratio of -55.07, a quick ratio of 0.48 and a current ratio of 0.04. The company has a fifty day simple moving average of C$0.11 and a two-hundred day simple moving average of C$0.12.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- How to Short Nasdaq: An Easy-to-Follow Guide
- Improving Fundamentals Drive New Buybacks for 3 Strong Performers
- What is the MACD Indicator and How to Use it in Your Trading
- 3 Reasons Gartner Could Be the Best Buy of Q3
- Where to Find Earnings Call Transcripts
- Free Cash Flow Boom Keeps Microsoft Ahead of the Pack
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
